Keywords
Coronary atherosclerotic heart disease
Atherosclerosis
Traditional chinese medicine
Treatment
Submitted : 2024-01-27
Accepted : 2024-02-11
Published : 2024-02-26
Abstract
The liver is in charge of distributing and regulating the movement of qi throughout the whole body, coordinating the transportation and transformation of the internal organs in the middle part of the body, promoting the biochemical circulation of qi, blood, and body fluids, and regulating emotions. Liver dysfunction can disrupt the transportation and transformation of qi, blood, and body fluids, causing phlegm turbidity, blood stasis, and other unwanted symptoms. Poor regulation of emotion further aggravates the accumulation of pathological substances, resulting in the obstruction of heart vessels, and ultimately coronary heart disease (CHD). Through regulating lipid metabolism, inflammatory reaction, vasoactive substances, platelet function, neuroendocrine, and other factors, liver controlling dispersing qi plays a comprehensive role in the prognosis of atherosclerosis, the primary cause of CHD. Therefore, it is recommended to treat CHD from the perspective of liver-controlling dispersion.
References
Xie X, Yang M, Chen J, et al., 2018, Advances in Modern Research on the Liver Function in Traditional Chinese Medicine and its Association with Other Organs. Modernization of Traditional Chinese Medicine and Materia-World Science and Technology, 20(12): 2185–2190.
Xiao K, Ren Y, Xu S, et al., 2022, The Modern Biological Interpretation of Liver Controlling Dispersion. World Chinese Medicine, 17(24): 3519–3523.
Huo L, Zhang H, Zhan X, et al., 2021, The Evolution of the Connotation of Liver Controlling Dispersion. Journal of Basic Chinese Medicine, 27(10): 1533–1535.
Zhao D, Ren J, An H, 2017, Tracing and Modern Research on the Origin and Development of Liver Controlling Dispersion. Journal of Basic Chinese Medicine, 23(02): 289–291.
Fan J, Liu J, Wang B, et al., 2018, Clinical Thinking of Treating Coronary Plaque with Balance Method by Yan Qianlin. Journal of Traditional Chinese Medicine, 59(24): 2085–2089.
Li W, Feng L, Wang Q, et al., 2020, Traditional Chinese Medicine Master Lu Zhizheng’s Treatment of Chest Bi from the Perspective of Liver and Spleen. China Journal of Traditional Chinese Medicine and Pharmacy, 35(9): 4432– 4435.
Guo H, Zheng Y, Zhang H, et al., 2020, Exploring the Medication Patterns of Professor Yu Rui in the Treatment of Chest Pain Based on Cluster Analysis. Chinese Archives of Traditional Chinese medicine, 38(02): 92–95.
Qi S, Luo X, Liu S, et al., 2022, The Critical Effect of Bile Acids in Atherosclerosis. J Cardiovasc Pharmacol, 80(4): 562–573.
Zhao Y, Shan Z, 2022, Exploring the Application of the Four-Way Method in the Treatment of Gallbladder Heart Syndrome. China Journal of Traditional Chinese Medicine and Pharmacy, 37(12): 7134–7136.
Meng X, Song N, Wang Y, et al., 2022, Study on The Mechanism and Prediction of Prevention and Treatment of Coronary Heart Disease Complicated with Depression Based on “Liver and Heart Treatment.” Chinese Archives of Traditional Chinese medicine, 41(8): 201–205 + 281.
Chao T, Zhang D, Sun J, et al., 2020, Modern Literature Research on TCM Syndromes and Syndrome Elements Distribution Characteristics of Coronary Heart Disease with Anxiety or Depressive Disorder. Modernization of Traditional Chinese Medicine and Materia-World Science and Technology, 22(5): 1405–1411.
Lei S, Xiang X, Wang L, et al., 2023, Distribution Characteristics of TCM Complex Patterns of 312 Patients with Coronary Heart Disease with Depression Based on Cross-Sectional Survey and Latent Structure Model. Journal of Beijing University of Traditional Chinese Medicine, 46(5): 720–730.
Feng S, Sun Z, Jia X, et al., 2023, Lipophagy: Molecular Mechanisms and Implications in Hepatic Lipid Metabolism. Front Biosci (Landmark Ed), 28(1): 6.
Zhang S, Hong F, Ma C, et al., 2022, Hepatic Lipid Metabolism Disorder and Atherosclerosis. Endocr Metab Immune Disord Drug Targets, 22(6): 590–600.
Olkowicz M, Czyzynska-Cichon I, Szupryczynska N, et al., 2021, Multi-omic Signatures of Atherogenic Dyslipidaemia: Pre-Clinical Target Identification and Validation in Humans. J Transl Med, 19(1): 6.
Xu C, Li H, Tang C K, 2023, Sterol Carrier Protein 2: A Promising Target in the Pathogenesis of Atherosclerosis. Genes Dis, 10(2): 457–467.
Grbic E, Gorkic N, Pleskovic A, et al., 2022, Association Between the rs2279238 of the Liver X Receptor Alpha Gene Polymorphism and Advanced Carotid Atherosclerosis in the Slovenian Cohort. Gene, 840: e146764.
Wang H, Huang Z, Ji M, et al., 2020, Effects of Chaihu-Shugan Decoction on ROCK/JNK Signaling Pathway and Atherosclerosis in Spontaneously Hypertensive Rats. Chinese Journal of Pathophysiology, 36(8): 1476–1481.
Zhao S, Zhang L, Feng W, et al., 2019, Effect of Shugan Wendan Decoction on LXR?, NF-?B, and Endothelial Function in Atherosclerosis Rabbits. Chinese Journal of Experimental Traditional Medical Formulae, 25(15): 108- 115.
Zhao S, Chen Y, Zhuang J, et al., 2022, The Effect of Shugan Wendan Tang on Vascular Endothelial Injury Induced by Motor Vehicle Exhaust in Rats. Chinese Journal of Gerontology, 42(19): 4741–4744.
Almog T, Keshet R, Kandel-Kfir M, et al., 2023, Gene Deletion of Interleukin-1? Reduces ER Stress-Induced CHOP Expression in Macrophages and Attenuates the Progression of Atherosclerosis in APOE-Deficient Mice. Cytokine, 167: 156212.
Gusev E, Sarapultsev A, 2023, Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. Int J Mol Sci, 24(9): 7910.
Wang L, Cheng C K, Yi M, et al.,2022, Targeting endothelial dysfunction and inflammation. J Mol Cell Cardiol, 168: 58-67.doi: 10.1016/j.yjmcc.2022.04.011.
Senatus L, Egana-Gorrono L, Lopez-Diez R, et al., 2023, DIAPH1 Mediates Progression of Atherosclerosis and Regulates Hepatic Lipid Metabolism in Mice. Commun Biol, 6(1): 280.
Higashi Y, 2022, Roles of Oxidative Stress and Inflammation in Vascular Endothelial Dysfunction-Related Disease. Antioxidants (Basel), 11(10): 1958.
Hasheminasabgorji E, Jha J C, 2021, Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS- Redox-Sensitive Factors. Biomedicines, 9(11): 1602.
Chen M, Luo Y, Men L, et al., 2021, Investigating the Mechanisms of Modified Xiaoyaosan (Tiaogan-Liqi Prescription) in Suppressing the Progression of Atherosclerosis, by Means of Integrative Pharmacology and Experimental Validation. Aging (Albany NY), 13(8): 11411–11432.
Steadman E, Yin W, 2022, Fluid Structure Interaction Study of Coronary Artery Disease Biomechanics. The FASEB Journal, 36(1).
Liang F, Hu D, Fang Q, et al., 2022, The Latest Progress in the Diagnosis and Treatment of Chronic Coronary Syndrome Based on European Guidelines. Chin J Evid Based Cardiovasc Med, 14(6): 761–768.
Hu F, Shen J, Hu L, et al., 2020, Clinical Study on the Treatment of Coronary Heart Disease Combined with Hyperlipidemia with Shugan Jianpi Tiaozhi Granules. Pharmacology and Clinics of Chinese Materia Medica, 36(6): 186–189.
Zhou X, Wang J, Wang Z, et al., 2019, Effect of Traditional Chinese Medicine on Treatment of Coronary Heart Disease and its Effect on Vascular Endothelial Function and Hemorheological Indexes. Chinese Archives of Traditional Chinese medicine, 37(1): 220–223.
Lin P, Yu R, Zhou X, 2022, Effect of Liver Dysfunction on Intestinal Microbiome Hematogenesis Disorder and Its Mechanism Based on TMA/FMO3/TMAO Pathway. Journal of Liaoning University of Traditional Chinese Medicine, 24(04): 56–59.
Lin L, Liu J,2019, Advances in Coronary Heart Disease with Anxiety/Depression State. Advances in Cardiovascular Diseases, 40(2): 248–252.
Yang P, Li L, Liu X J, et al., 2016, Effect of Chaihu-Shugan-San on the mRNA Expression of the 5-HT1A Receptor and Cellular Proliferation in the Hippocampus of Epileptic Rats with Depression. Exp Ther Med, 11(1): 124–130.